3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
4
Gastrointestinal
3
Myeloid
2
Lymphoid
2
Genitourinary
2
CNS
2
Thoracic
1
Head & Neck
1
Dermatologic
1
Breast
1
Conditions
Thyroid Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Multiple Myeloma
1
Lymphoma
1
Hematologic Neoplasms
1
Glioma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
11
Cyclophosphamide
8
Gemcitabine
7
Cisplatin
7
tislelizumab
5
Docetaxel
5
Nivolumab
4
Injections
4
spartalizumab
3
regorafenib
3
Trastuzumab
3
Oncolytic Virotherapy
3
Irinotecan
3
Filgrastim
3
Drug Therapy
3
Doxorubicin
3
Carboplatin
3
Bortezomib
3
tazemetostat
2
pazopanib
2
liposomal doxorubicin
2
ganitumab
2
conatumumab
2
belinostat
2
Temozolomide
2
Taxes
2
Tamoxifen
2
Sorafenib
2
Riluzole
2
Radiotherapy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
larotrectinib
×
Thoracic
×
Clear all
NCT02576431
2026-04-28
NAVIGATE
Bayer
Phase 2
Completed
215 enrolled
2 FDA